40 patents currently held
108 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Sep 2035. from the record
Of the 108 now held by other companies, 83 name Valo Health Inc. as their current owner, and 25 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
0
Ending by 2030
Sep 2035
Next term end
15
Patent families
When these terms end
Held patents by the year their term ends
notable patents
fee due within 90 days
all others
Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Notable: the highest-ranked patents in this portfolio by citations and family size. Fee due within 90 days: a maintenance fee is due within 90 days of when this page was computed and not yet paid.
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Notable
Ends May 2039 · High confidence
Also notable
Ends Nov 2036 · High confidence
Also notable
Ends Oct 2037 · High confidence
Also notable
Ends Sep 2038 · High confidence
Also notable
Ends Oct 2039 · High confidence
Also notable
Ends Jun 2039 · High confidence
Also notable
Ends Sep 2041 · High confidence
Also notable
Ends Oct 2041 · High confidence
Inhibiting Mutant IDH-1
US 11,576,906
Cited by 12 later US patents, top 10% of utility patents granted in 2023 in our data. Protection runs to 2039. A terminal disclaimer caps this term to an earlier patent's.
Purinones as Ubiquitin-Specific Protease 1 Inhibitors
US 10,189,841
Cited by 12 later US patents, top 25% of utility patents granted in 2019 in our data. Protection runs to 2036.
Methods Using HDAC11 Inhibitors
US 11,345,672
A family of 5 related applications built on the 2022 grant. Protection runs to 2037.
Tetrahydro-Imidazo Quinoline Compositions as CBP/P300 Inhibitors
US 11,292,791
Cited by 5 later US patents, top 25% of utility patents granted in 2022 in our data. Protection runs to 2038.
Fused Pyrrolines Which Act as Ubiquitin-Specific Protease 30 (USP30) Inhibitors
US 11,535,618
Granted 2022. Computed term ends 2039.
Inhibiting Creb Binding Protein (CBP)
US 10,870,648
Granted 2020. Computed term ends 2039.
Inhibiting Cyclic Amp-Responsive Element-Binding Protein (CREB) Binding Protein (CBP)
US 11,795,168
Granted 2023. Computed term ends 2041.
Bromodomain Inhibitors for Androgen Receptor-Driven Cancers
US 11,801,243
Granted 2023. Computed term ends 2041.
Formerly held, still cited
Notable
Ends Feb 2036 · High confidence
Cited by 73 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2036.
now held by Valo Health, Inc.
Also notable
Ends Feb 2036 · High confidence
Cited by 72 later US patents, top 5% of utility patents granted in 2019 in our data, and renewed at 2 of 3 maintenance windows. Protection runs to 2036.
now held by Valo Health, Inc.
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 2 fees due Feb 15 to 28, 2027 · next Feb 15
- 2 fees due Mar 3 to 17, 2027 · next Mar 3
- 3 fees due Apr 17 to 30, 2027 · next Apr 17
- 1 fee due May 14, 2027The maintenance fee for Fused Pyrrolines Which Act as Ubiquitin-Specific Protease 30 (USP30) Inhibitors (US 11,814,386) comes due May 14, 2027. Unpaid by Nov 15, 2027, it lapses early.
- 1 fee due Jul 14, 2027The maintenance fee for Solid Forms of ((S)-5-((1-(6-Chloro-2-OXO-1,2-Dihydroquinolin-3-YL)ETHYL)AMINO)-1-Methyl-6-OXO-1,6-Dihydropyridine-2-Carbonitrile (US 10,532,047) comes due Jul 14, 2027. Unpaid by Jan 14, 2028, it lapses early.
- 1 fee due Aug 4, 2027The maintenance fee for PYRIDIN-2(1H)-ONE Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors (US 10,550,098) comes due Aug 4, 2027. Unpaid by Feb 4, 2028, it lapses early.
- 1 fee due Oct 23, 2027The maintenance fee for Inhibiting Mutant Isocitrate Dehydrogenase 1 (mIDH-1) (US 11,963,956) comes due Oct 23, 2027. Unpaid by Apr 24, 2028, it lapses early.
- 1 fee due Nov 14, 2027The maintenance fee for Treating Sickle Cell Disease with a Pyruvate Kinase R Activating Compound (US 11,980,611) comes due Nov 14, 2027. Unpaid by May 15, 2028, it lapses early.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
The largest of its 15 families, grouped by real patent family and labeled by the earliest filing in each. No technology classification is inferred from titles.
Patents held now
Soonest term end first.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,834,539 | PYRIDIN-2(1H)-ONE Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors In force · High confidence | In force | High confidence | |
| US 10,414,752 | PYRIDIN-2(1H)-ONE Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors In force · Low confidence | In force | Low confidence | |
| US 10,550,098 | PYRIDIN-2(1H)-ONE Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors In force · Low confidence | In force | Low confidence | |
| US 10,889,567 | PYRIDIN-2(1H)-ONE Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors In force · Low confidence | In force | Low confidence | |
| US 11,498,913 | PYRIDIN-2(1H)-ONE Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors In force · Low confidence | In force | Low confidence | |
| US 12,275,715 | PYRIDIN-2(1H)-ONE Quinolinone Derivatives as Mutant-Isocitrate Dehydrogenase Inhibitors In force · Low confidence | In force | Low confidence | |
| US 10,189,841 | Purinones as Ubiquitin-Specific Protease 1 Inhibitors In force · High confidence | In force | High confidence | |
| US 10,399,980 | Purinones as Ubiquitin-Specific Protease 1 Inhibitors In force · High confidence | In force | High confidence | |
| US 11,161,848 | Purinones as Ubiquitin-Specific Protease 1 Inhibitors In force · Low confidence | In force | Low confidence | |
| US 12,043,623 | Purinones as Ubiquitin-Specific Protease 1 Inhibitors In force · Low confidence | In force | Low confidence |
Also on record, not counted in the 40: 108 patents in force now held by others · 33 patents ended · 9 applications pending · 53 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Fee due within 90 days marks a patent with a maintenance fee due within 90 days of the date this page was computed and not yet recorded paid, so it can end earlier than the bar shows. A fee left unpaid ends the patent at the close of the six month grace period that follows its due date, not on the due date itself. It is not a prediction that the fee will be missed.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.